Molecular Profile Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Profile Name	EML4 - ALK ALK D1203N
Gene Variant Detail	ALK D1203N (unknown) EML4 - ALK (gain of function)
Relevant Treatment Approaches	Alectinib Brigatinib Ceritinib Lorlatinib

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 16 of 16 entries

Molecular Profile	Indication/Tumor Type	Response Type	Relevant Treatment Approaches	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
EML4 - ALK ALK D1203N	lung adenocarcinoma	predicted - resistant		Crizotinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with metastatic lung adenocarcinoma harboring EML4-ALK (e19:e20) who responded to Xalkori (crizotinib) treatment was found to have acquired ALK D1203N upon disease progression (PMID: 38149055).	38149055
EML4 - ALK ALK D1203N	lung adenocarcinoma	predicted - sensitive	Lorlatinib	Lorlatinib	Case Reports/Case Series	Actionable	In a clinical case study, Lorbrena (lorlatinib) treatment resulted in a partial response and progression-free survival of 19 months in a patient with metastatic lung adenocarcinoma harboring EML4-ALK (e19:e20) and ALK D1203N (PMID: 38149055).	38149055
EML4 - ALK ALK D1203N	Advanced Solid Tumor	predicted - resistant		Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK D1203N demonstrated a decreased response to treatment with Xalkori (crizotinib) compared to cells expressing EML4-ALK in culture (PMID: 27432227).	27432227
EML4 - ALK ALK D1203N	Advanced Solid Tumor	sensitive	Ceritinib	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK D1203N demonstrated sensitivity to treatment with Zykadia (ceritinib) in culture (PMID: 27432227).	27432227
EML4 - ALK ALK D1203N	Advanced Solid Tumor	sensitive	Alectinib	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK D1203N demonstrated sensitivity to treatment with Alecensa (alectinib) in culture (PMID: 27432227).	27432227
EML4 - ALK ALK D1203N	Advanced Solid Tumor	sensitive	Brigatinib	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK D1203N demonstrated sensitivity to treatment with Alunbrig (brigatinib) in culture (PMID: 27432227).	27432227
EML4 - ALK ALK D1203N	Advanced Solid Tumor	sensitive	Lorlatinib	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK D1203N demonstrated sensitivity to treatment with Lorbrena (lorlatinib) in culture (PMID: 27432227).	27432227
EML4 - ALK ALK D1203N	Advanced Solid Tumor	resistant		TAE684	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells overexpressing ALK D1203N in the context of EML4-ALK were resistant to TAE684 in culture (PMID: 21948233).	21948233
EML4 - ALK ALK D1203N	Advanced Solid Tumor	predicted - resistant		Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK D1203N were resistant to treatment with Xalkori (crizotinib) in culture (PMID: 33627640).	33627640
EML4 - ALK ALK D1203N	Advanced Solid Tumor	resistant		Entrectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK D1203N were resistant to treatment with Rozlytrek (entrectinib) in culture (PMID: 33627640).	33627640
EML4 - ALK ALK D1203N	Advanced Solid Tumor	predicted - resistant		Gilteritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK D1203N demonstrated resistance to treatment with Xospata (gilteritinib) in culture (PMID: 33627640).	33627640
EML4 - ALK ALK D1203N	Advanced Solid Tumor	sensitive	Alectinib	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alecensa (alectinib) inhibited viability of transformed cells expressing EML4-ALK with ALK D1203N in culture (PMID: 33627640).	33627640
EML4 - ALK ALK D1203N	Advanced Solid Tumor	sensitive	Lorlatinib	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Lorbrena (lorlatinib) inhibited viability of transformed cells expressing EML4-ALK with ALK D1203N in culture (PMID: 33627640).	33627640
EML4 - ALK ALK D1203N	Advanced Solid Tumor	sensitive	Brigatinib	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited viability of transformed cells expressing EML4-ALK with ALK D1203N in culture (PMID: 33627640).	33627640
EML4 - ALK ALK D1203N	Advanced Solid Tumor	sensitive	Ceritinib	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited viability of transformed cells expressing EML4-ALK with ALK D1203N in culture (PMID: 33627640).	33627640
EML4 - ALK ALK D1203N	Advanced Solid Tumor	predicted - sensitive		NVL-655	Preclinical - Cell culture	Actionable	In a preclinical study, NVL-655 moderately inhibited viability of cells expressing EML4-ALK and ALK D1203N in culture (PMID: 39269178).	39269178

Showing 1 to 16 of 16 entries

Filter rows: